CN115501288A - Method for extracting callicarpa nudiflora extract and application of extract in resisting H1N1 virus - Google Patents
Method for extracting callicarpa nudiflora extract and application of extract in resisting H1N1 virus Download PDFInfo
- Publication number
- CN115501288A CN115501288A CN202211198464.9A CN202211198464A CN115501288A CN 115501288 A CN115501288 A CN 115501288A CN 202211198464 A CN202211198464 A CN 202211198464A CN 115501288 A CN115501288 A CN 115501288A
- Authority
- CN
- China
- Prior art keywords
- ethyl acetate
- callicarpa nudiflora
- extract
- filtrate
- filter residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to the technical field of medicines, in particular to an extraction method of a callicarpa nudiflora extract and application of the extract in resisting H1N1 virus, wherein callicarpa nudiflora is taken, crushed, sieved, added with ethanol, soaked, extracted by reflux and filtered to obtain a first filtrate and a first filter residue; adding ethanol into the first filter residue, and performing reflux extraction and filtration to obtain a second filtrate and a second filter residue; adding water into the second filter residue, and performing reflux extraction and filtration to obtain a third filtrate; and combining the first filtrate, the second filtrate and the third filtrate to obtain a concentrated solution, extracting the concentrated solution with petroleum ether and ethyl acetate respectively, and evaporating and concentrating the concentrated solution to be dried in a water bath to obtain a callicarpa nudiflora ethyl acetate extract. Therefore, the invention can effectively relieve lung tissue injury caused by H1N1 infection, inhibit excessive inflammatory reaction, enhance immunity, obviously reduce the virus load of lung tissue and inhibit the proliferation of virus in lung.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to an extraction method of a callicarpa nudiflora extract and application of the extract in resisting H1N1 virus.
Background
Influenza A Virus (IAV) infection is a common cause of pneumonia-associated death cases, and severe IAV infection causes bilateral pulmonary infiltration and hypoxemia, i.e., acute respiratory distress syndrome, which is one of the major causes of death due to IAV. It is estimated that the total incidence of acute respiratory distress syndrome caused by seasonal IAV infection is 2.7 cases per 10 million people. Typical symptoms of H1N 1-infected persons include persistent or repeated fever, cough, sometimes with sore throat and nasal discharge, dyspnea, etc., and symptoms of gastrointestinal tract (including nausea, vomiting and diarrhea) are also present in epidemic H1N1 infection.
Currently, drugs approved for clinical prevention and treatment of influenza include M2 channel inhibitors (such as amantadine and rimantadine) and NA inhibitors, and M2 channel inhibitors are no longer recommended for treatment of influenza due to their wide drug resistance, and reports on viral resistance of NA inhibitors such as oseltamivir are also rapidly increasing.
How to effectively reduce lung tissue injury caused by H1N1 infection, inhibit excessive inflammatory reaction, enhance immunity, obviously reduce the viral load of lung tissue and inhibit the proliferation of viruses in the lung is a technical problem needing to be broken through.
In view of the above, the prior art is obviously inconvenient and disadvantageous in practical use, and needs to be improved.
Disclosure of Invention
In view of the above-mentioned drawbacks, the present invention aims to provide an extraction method of beautyberry extract and an application of the extract in resisting H1N1 virus, which can effectively alleviate lung tissue damage caused by H1N1 infection, inhibit excessive inflammatory reaction, enhance immunity, significantly reduce viral load of lung tissue, and inhibit proliferation of virus in lung.
In order to achieve the above object, the present invention provides a method for extracting callicarpa nudiflora extract, comprising the steps of:
step one extraction of Callicarpa nudiflora
Taking a callicarpa nudiflora medicinal material, crushing and sieving the callicarpa nudiflora medicinal material, adding 94-96% ethanol, wherein the mass ratio of callicarpa nudiflora medicinal material powder to ethanol is 1: 7-9, soaking, reflux extracting and filtering to obtain a first filtrate and a first filter residue; adding 70-80% of ethanol into the first filter residue, wherein the mass ratio of the first filter residue to the ethanol is 1: 7-9, performing reflux extraction and filtering to obtain a second filtrate and a second filter residue; adding water into the second filter residue, wherein the mass ratio of the second filter residue to the water is 1: 7-9, and carrying out reflux extraction and filtration to obtain a third filtrate.
And combining the first filtrate, the second filtrate and the third filtrate, and evaporating and concentrating to obtain a concentrated solution.
Step two extraction of effective components
Adding petroleum ether into the concentrated solution, wherein the volume ratio of the petroleum ether to the concentrated solution is 1:0.8 to 1.2, extracting and separating by using petroleum ether, and reserving a water phase.
Adding ethyl acetate into the water phase extracted by the petroleum ether, wherein the volume ratio of the ethyl acetate to the water phase extracted by the petroleum ether is 1: 0.8-1.2, extracting and separating by using ethyl acetate, reserving an ethyl acetate extraction layer to obtain an ethyl acetate extract, and evaporating the ethyl acetate extract and volatilizing in water bath to obtain the callicarpa nudiflora ethyl acetate extract.
According to the extraction method of the callicarpa nudiflora extract, the granularity of the crushed and sieved callicarpa nudiflora is 30-50 meshes.
According to the extraction method of the callicarpa nudiflora extract, the apparatuses adopted for evaporation and concentration are all rotary evaporators.
According to the extraction method of the callicarpa nudiflora extract, the extraction times of the petroleum ether and the ethyl acetate are 3 times.
According to the extraction method of the callicarpa nudiflora extract, the soaking time is 30-35 minutes.
According to the extraction method of the callicarpa nudiflora extract, the reflux extraction time is 110-130 minutes.
According to the extraction method of the callicarpa nudiflora extract, the optimal mass ratio of the callicarpa nudiflora medicinal material powder to ethanol, the optimal mass ratio of the first filter residue to ethanol, and the optimal mass ratio of the second filter residue to water are all 1:8.
According to the extraction method of the callicarpa nudiflora extract, the optimal volume ratio of the petroleum ether to the concentrated solution and the optimal volume ratio of the ethyl acetate to the aqueous phase extracted by the petroleum ether are both 1:1.
an application of an ethyl acetate extract of Callicarpa nudiflora in resisting H1N1 virus is provided.
The invention aims to provide an extraction method of callicarpa nudiflora extract and application of the extract in resisting H1N1 virus, which comprises the steps of taking callicarpa nudiflora medicinal material, crushing, repeatedly extracting in ethanol, evaporating and concentrating, finally extracting in petroleum ether and ethyl acetate respectively, evaporating and concentrating, and volatilizing in water bath to obtain callicarpa nudiflora ethyl acetate extract; the ethyl acetate extract of callicarpa nudiflora can effectively relieve lung tissue injury caused by H1N1 infection, inhibit excessive inflammatory reaction, enhance immunity, remarkably reduce virus load of lung tissue, inhibit virus proliferation in lung, and exert the effect of resisting H1N1 from multiple ways such as directly inhibiting virus, resisting inflammation and enhancing immunity. In conclusion, the beneficial effects of the invention are as follows: can effectively relieve lung tissue injury caused by H1N1 infection, inhibit excessive inflammatory reaction, enhance immunity, remarkably reduce virus load of lung tissue, and inhibit virus proliferation in lung.
Drawings
FIG. 1 is a graph showing the anti-H1N 1 effect of ethyl acetate extract of Callicarpa nudiflora;
FIG. 2 is a graph showing the effect of ethyl acetate extract of beautyberry on reducing the weight loss of mice;
FIG. 3 is a graph showing the effect of ethyl acetate extract of beautyberry on reducing the lung index of mice;
FIG. 4 is a graph showing the effect of ethyl acetate extract of Callicarpa nudiflora on the reduction of mouse TNF- α;
FIG. 5 is a graph showing the effect of ethyl acetate extract of Callicarpa nudiflora on the reduction of IL-1 β in mice;
FIG. 6 is a graph showing the effect of ethyl acetate extract of Callicarpa nudiflora on the reduction of mouse IFN-. Gamma.;
FIG. 7 is a graph showing the effect of ethyl acetate extract of Callicarpa nudiflora on reducing H1N1 viral load in mouse lung;
FIG. 8 is a graph showing the effect of ethyl acetate extract of Callicarpa nudiflora on increasing mouse serum IgG levels;
FIG. 9 is a graph showing the effect of ethyl acetate extract of Callicarpa nudiflora on increasing the spleen index of mice;
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail below with reference to the accompanying drawings. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Referring to fig. 1, the invention provides a preparation method of an anti-H1N 1 callicarpa nudiflora effective part, which comprises the following steps:
step one extraction of Callicarpa nudiflora
Taking a callicarpa nudiflora medicinal material, crushing, sieving with a 30-50-mesh sieve to obtain callicarpa nudiflora medicinal material powder, adding 94-96% ethanol (the mass ratio of the callicarpa nudiflora medicinal material powder to the ethanol is 1: 7-9) into the callicarpa nudiflora medicinal material powder, soaking for 30-35 minutes, performing reflux extraction for 110-130 minutes, and filtering to obtain a first filtrate and a first filter residue; adding 70-80% ethanol (the mass ratio of the first filter residue to the ethanol is 1-7-9) into the first filter residue, performing reflux extraction for 110-130 minutes, and filtering to obtain a second filtrate and a second filter residue; and adding water into the second filter residue (the mass ratio of the second filter residue to the water is 1.
And combining the first filtrate, the second filtrate and the third filtrate, and evaporating and concentrating by using a rotary evaporator to obtain a concentrated solution.
Step two extraction of effective components
Adding petroleum ether (the volume ratio of the petroleum ether to the concentrated solution is 1: 0.8-1.2) into the concentrated solution, extracting for 3-4 times by using the petroleum ether, separating, and retaining a water phase;
adding ethyl acetate (the volume ratio of the ethyl acetate to the petroleum ether-extracted water phase is 1.8-1.2) into the first water phase, extracting with ethyl acetate for 3-4 times, separating, and reserving an ethyl acetate extraction layer to obtain an ethyl acetate extract. And recovering ethyl acetate from the ethyl acetate extract by using a rotary evaporator, and volatilizing in a water bath to obtain the callicarpa nudiflora ethyl acetate extract.
Preferably, the optimal mass ratio of the callicarpa nudiflora medicinal material powder to the ethanol, the optimal mass ratio of the first filter residue to the ethanol, and the optimal mass ratio of the second filter residue to the water are all 1:8.
preferably, the optimal volume ratio of the petroleum ether to the concentrated solution and the optimal volume ratio of the ethyl acetate to the petroleum ether extracted water phase are both 1:1.
in order to verify the medicinal value of the callicarpa nudiflora ethyl acetate extract, the prepared callicarpa nudiflora ethyl acetate extract is subjected to in vitro anti-H1N 1 performance test and in vivo anti-H1N 1 performance test.
In vitro anti-H1N 1 Performance test (see FIG. 1)
Virus strain: influenza A H1N1 murine lung adapted strain (A/PR/8/1934).
Recovery and passage of host cell MDCK
The MDCK cells stored in a refrigerator with the temperature of minus 80 ℃ are placed in warm water with the temperature of 37 ℃ for unfreezing, centrifuged (1000 r/min) for 5min, supernatant is removed, the cells are transferred to a cell culture bottle, 5mL of cell culture solution is added, the cell culture bottle is placed in a cell culture box, the cells are cultured until a monolayer grows to 70-80% of the bottom area of the culture bottle, after the cells are washed by PBS, the cells are rinsed once by 0.5mL of pancreatin, and then 1mL of pancreatin is added into the culture box for incubation for 6-8 min. Adding 2mL of cell culture solution into the cells after enzymolysis, blowing and beating uniformly, discarding 1/3-1/2 of the culture solution, supplementing the cell culture solution to 5mL, and completing one cell passage. After three passages, the cells were seeded in 96 wellsPlate, concentration 1.0X 10 4 Individual cell/well
Determination of drug toxicity
The four extracts and oseltamivir phosphate were inoculated into MDCK cells at different concentrations and cultured for 48 hours. The four extracts and oseltamivir phosphate were tested for 50% cytotoxic concentration (CC 50) against MDCK cells using MTT kit. The maximum drug concentration for which cell viability is greater than 90% is selected as the non-cytotoxic concentration of the drug. The CC50 of the ethyl acetate extract on MDCK cells was found to be 0.86mg/mL.
Study of anti-H1N 1 Effect
Inoculating 96-well plate at a concentration of 1 × 10 5 Cell suspension 100. Mu.L/mL, cultured for 24h (37 ℃,5% CO) 2 ). The process of H1N1 infection of MDCK cells was performed in Opti-MEM medium containing 1000U/mL penicillin, 100. Mu.g/mL streptomycin, and 2. Mu.g/mL LTPCK-pancreatin. Cell plates grown to 80% or more cells were discarded from the cell culture solution and washed twice with PBS, and 100. Mu.L of each extract or oseltamivir phosphate solution of different concentrations and 100. Mu.L of virus dilution 1N1 (1X 10 from TCID 50) were added to each well 6 Was obtained by 100-fold dilution of the virus stock). After 48H of culture, the cell survival rate is detected by using an MTT kit, and the half inhibition concentration of the four extracts and oseltamivir phosphate on H1N1 is calculated according to a Reed-Muench method. It was found that the EC50 of the ethyl acetate extract against H1N1 was 0.051mg/mL, and the TI (CC 50/EC 50) value was 16.86.
In vivo anti-H1N 1 Performance test (see FIGS. 2-9)
Establishment of H1N1 infected mouse model
Randomly dividing mice into normal group, model group, callicarpa nudiflora ethyl acetate extraction part high, medium, low, dosage group, and oseltamivir phosphate group (32 mg/kg), feeding 10 mice per group adaptively for 3 days, anesthetizing with animal anesthesia machine (anesthetic is isoflurane), collecting H1N1 virus stock solution, diluting 100 times, and dripping nose infection virus 20 μ L (LD 50 of virus is 10) -3 /mL, i.e. diluting the virus solution by 10 3 And (4) inoculating 20 mu L of the virus, so that half of mice can die, wherein the virus infection amount of the experimental mice is 10LD 50), and the stomach is perfused and administered with 0.2mL after 2 hours of virus infection.
In vivo anti-H1N 1 Effect study
After continuous intragastric administration for 6 days, the mice are killed by removing necks, lung tissues of the mice are taken and weighed, lung indexes (lung weight/body weight multiplied by 100%) are calculated, two lungs on one side close to the heart are taken and fixed by paraformaldehyde, and HE staining is carried out after dehydration, tissue transparency, wax dipping, embedding, slicing and drying to observe pathological changes of the lungs of the mice. The H1N1 viral load of the lung tissue of the mice was measured, and the level of the peripheral blood inflammatory factor of the mice was measured. The beautyberry ethyl acetate extract can obviously reduce the increase of lung index caused by H1N1 infection, increase the spleen index of a mouse, reduce the H1N1 virus load of a mouse lung tissue and reduce the level of inflammatory factors in peripheral blood.
According to the experimental results, after the H1N1 virus invades the organism, a series of inflammatory injuries are caused by the induction of inflammatory factors such as IL-1 beta, TNF-alpha, IFN-gamma and the like, and the lung index is increased due to the inflammatory infiltration of lung tissues. The ethyl acetate extract of callicarpa nudiflora can obviously inhibit the increase of inflammatory factors, reduce the lung index and relieve inflammatory injury caused by H1N1 infection. The proliferation condition of H1N1 in the lung of a mouse is detected by using a q-PCR method, and the ethyl acetate extract of callicarpa nudiflora can obviously reduce the virus load of H1N1 in the lung tissue of the mouse, so that the ethyl acetate extract can inhibit the proliferation of H1N1 in the lung of the mouse. The antibody produced by an organism under the stimulation of influenza virus mainly comprises IgG, and the ethyl acetate extract of the callicarpa nudiflora can obviously increase the IgG level of the serum of a mouse and increase the spleen index of the mouse, so that the ethyl acetate extract of the callicarpa nudiflora can enhance the immune response of the mouse. This suggests that the ethyl acetate extract of callicarpa nudiflora can exert an anti-H1N 1 effect through a number of routes including direct virus inhibition, anti-inflammation, and immune enhancement.
The invention provides an extraction method of callicarpa nudiflora extract and application of the extract in resisting H1N1 virus, which comprises the steps of taking callicarpa nudiflora medicinal material, repeatedly extracting in ethanol after crushing, evaporating and concentrating, finally extracting in petroleum ether and ethyl acetate respectively, and obtaining the callicarpa nudiflora ethyl acetate extract after evaporating and concentrating and volatilizing in water bath; the ethyl acetate extract of callicarpa nudiflora can effectively relieve lung tissue injury caused by H1N1 infection, inhibit excessive inflammatory reaction, enhance immunity, remarkably reduce virus load of lung tissue, inhibit virus proliferation in lung, and exert the effect of resisting H1N1 from multiple ways such as directly inhibiting virus, resisting inflammation and enhancing immunity. In conclusion, the beneficial effects of the invention are as follows: can effectively relieve lung tissue injury caused by H1N1 infection, inhibit excessive inflammatory reaction, enhance immunity, remarkably reduce virus load of lung tissue, and inhibit virus proliferation in lung.
The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof, and it should be understood that various changes and modifications can be effected therein by one skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (9)
1. The extraction method of the callicarpa nudiflora extract is characterized by comprising the following steps:
step one extraction of Callicarpa nudiflora
Taking a callicarpa nudiflora medicinal material, crushing and sieving the callicarpa nudiflora medicinal material, adding 94-96% ethanol, wherein the mass ratio of callicarpa nudiflora medicinal material powder to ethanol is 1: 7-9, soaking, reflux extracting and filtering to obtain a first filtrate and a first filter residue; adding 70-80% of ethanol into the first filter residue, wherein the mass ratio of the first filter residue to the ethanol is 1: 7-9, performing reflux extraction and filtering to obtain a second filtrate and a second filter residue; adding water into the second filter residue, wherein the mass ratio of the second filter residue to the water is 1: 7-9, performing reflux extraction and filtering to obtain a third filtrate;
combining the first filtrate, the second filtrate and the third filtrate, and evaporating and concentrating to obtain a concentrated solution;
step two extraction of effective components
Adding petroleum ether into the concentrated solution, wherein the volume ratio of the petroleum ether to the concentrated solution is 1:0.8 to 1.2, extracting and separating by using petroleum ether, and reserving a water phase;
adding ethyl acetate into the water phase extracted by the petroleum ether, wherein the volume ratio of the ethyl acetate to the water phase extracted by the petroleum ether is 1: 0.8-1.2, extracting and separating by using ethyl acetate, reserving an ethyl acetate extraction layer to obtain an ethyl acetate extract, and evaporating the ethyl acetate extract and volatilizing in water bath to obtain the callicarpa nudiflora ethyl acetate extract.
2. The method for extracting callicarpa nudiflora extract as claimed in claim 1, wherein the size of the crushed and sieved sieve is 30-50 mesh.
3. The method for extracting callicarpa nudiflora extract according to claim 1, wherein the evaporation and concentration are performed using a rotary evaporator.
4. The method of claim 1, wherein the petroleum ether and ethyl acetate are extracted 3 times each.
5. The method for extracting beautyberry extract according to claim 1, wherein the soaking time is 30 to 35 minutes.
6. The method for extracting callicarpa nudiflora extract according to claim 1, wherein the time of the reflux extraction is 110 to 130 minutes.
7. The extraction method of beautyberry extract according to claim 1, wherein the optimal mass ratio of beautyberry medicinal material powder to ethanol, the optimal mass ratio of the first filter residue to ethanol, and the optimal mass ratio of the second filter residue to water are all 1:8.
8. the method of claim 1, wherein the optimal volume ratio of petroleum ether to concentrate and the optimal volume ratio of ethyl acetate to petroleum ether-extracted aqueous phase are each 1:1.
9. use of the ethyl acetate extract according to claim 1 for anti-H1N 1 virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211198464.9A CN115501288B (en) | 2022-09-29 | 2022-09-29 | Extraction method of callicarpa nudiflora extract and application of extract in resisting H1N1 virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211198464.9A CN115501288B (en) | 2022-09-29 | 2022-09-29 | Extraction method of callicarpa nudiflora extract and application of extract in resisting H1N1 virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115501288A true CN115501288A (en) | 2022-12-23 |
| CN115501288B CN115501288B (en) | 2023-07-04 |
Family
ID=84508911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211198464.9A Active CN115501288B (en) | 2022-09-29 | 2022-09-29 | Extraction method of callicarpa nudiflora extract and application of extract in resisting H1N1 virus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115501288B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106266262A (en) * | 2015-06-05 | 2017-01-04 | 九芝堂股份有限公司 | A kind of Callicarpa nudiflora extract with antiinflammatory action |
| CN106924448A (en) * | 2017-01-10 | 2017-07-07 | 湖南华纳大药厂天然药物有限公司 | Treat pharmaceutical composition of anemopyretic cold and preparation method thereof |
| CN108686045A (en) * | 2018-07-03 | 2018-10-23 | 江西普正制药有限公司 | A kind of callicarpa nudiflora composition and its application for treating pharyngitis |
-
2022
- 2022-09-29 CN CN202211198464.9A patent/CN115501288B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106266262A (en) * | 2015-06-05 | 2017-01-04 | 九芝堂股份有限公司 | A kind of Callicarpa nudiflora extract with antiinflammatory action |
| CN106924448A (en) * | 2017-01-10 | 2017-07-07 | 湖南华纳大药厂天然药物有限公司 | Treat pharmaceutical composition of anemopyretic cold and preparation method thereof |
| CN108686045A (en) * | 2018-07-03 | 2018-10-23 | 江西普正制药有限公司 | A kind of callicarpa nudiflora composition and its application for treating pharyngitis |
Non-Patent Citations (4)
| Title |
|---|
| BAO-HONG LI，等: "Progress in Traditional Chinese Medicine Against Respiratory Viruses: A Review", FRONT PHARMACOL., vol. 12, pages 1 - 17 * |
| YING YANG，等: "Callicarpa nudiflora Hook. & Arn.: A comprehensive review of its phytochemistry and pharmacology", JOURNAL OF ETHNOPHARMACOLOGY, vol. 264, pages 1 - 15 * |
| 杨颖，等: "裸花紫珠乙酸乙酯部位人工胃肠液处理前后化学成分及抗EV71活性研究", 中华中医药杂志, vol. 37, no. 05, pages 2769 - 2773 * |
| 赵方舒，等: "金贝口服液抗小鼠甲型H1N1流感病毒及继发性肺炎链球菌感染作用研究", 中国药房, vol. 33, no. 21, pages 2622 - 2626 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115501288B (en) | 2023-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768308B (en) | A kind of pharmaceutical composition that is used for the treatment of the infection of the upper respiratory tract and preparation method thereof | |
| CN102961439A (en) | Total flavone extract of Hyssopus officinalis, preparation method thereof and application thereof | |
| CN104415130A (en) | Reduning injection and preparation method thereof | |
| CN103028001B (en) | It is a kind of be used for relieving asthma, the Chinese prescription of antibechic, anti-inflammatory, Its Preparation Method And Use | |
| CN108066434B (en) | Ganoderma lucidum traditional Chinese medicine composition with sleep improving effect and preparation method thereof | |
| CN102462728A (en) | Medicinal composition for treating and preventing bacterial upper respiratory tract infection | |
| CN115501288A (en) | Method for extracting callicarpa nudiflora extract and application of extract in resisting H1N1 virus | |
| WO2013159730A1 (en) | Food for nutritional therapy of aids | |
| CN115105502B (en) | Application of compound containing stephania plant alkaloid in preparation of cat infectious peritonitis medicine | |
| CN107753823B (en) | Traditional Chinese medicine composition for treating or preventing hand-foot-and-mouth disease | |
| CN102198192B (en) | Traditional Chinese medicine composition for treating HINI and application thereof | |
| CN103272196B (en) | Toxin-eliminating drug composition, drug preparation and preparation methods of drug composition and drug preparation | |
| CN102600210B (en) | A kind of compound DM Cough agent and preparation method thereof | |
| CN115212247B (en) | Preparation of nitraria tangutorum bobr and application thereof | |
| JP2010502655A (en) | Application of Solidago radish in the preparation of drugs for antiviral treatment and prevention | |
| CN101450093A (en) | Use of epomedium total-flavone in preparing target organ protection medicine | |
| CN110237201A (en) | A kind of drug for treating chronic pulmonary aspergilosis | |
| CN116650577B (en) | Application of calyx seu fructus physalis extract in resisting infectious bronchitis virus | |
| CN103784712A (en) | Health care product capable of repairing lung injuries caused by environmental pollution and preparation method of health care product | |
| CN108339026A (en) | A kind of herbal medicine compound injection and preparation method thereof and new application | |
| CN114177171B (en) | Application of pricklyash peel in preparation of medicines for treating and/or preventing pneumoviral pneumonia | |
| CN101982187B (en) | Walnut shell extract and anti-HIV pharmaceutical application thereof | |
| CN107198728A (en) | Chinese medicine preparation for treating children's upper respiratory tract infection and preparation method thereof | |
| CN1403129A (en) | Chinese medicine prepn for stopping drug addiction | |
| CN109078051B (en) | Application of pharmaceutical composition in preparation of antiviral drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |